Future Science OA最新文献_第8页

Lower birth rate, greater female dementia risk: global and regional patterns and public health implications. 出生率越低，女性患痴呆症的风险越大：全球和区域模式及公共卫生影响。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-25 DOI: 10.1080/20565623.2025.2550897

Wenpeng You

{"title":"Lower birth rate, greater female dementia risk: global and regional patterns and public health implications.","authors":"Wenpeng You","doi":"10.1080/20565623.2025.2550897","DOIUrl":"10.1080/20565623.2025.2550897","url":null,"abstract":"Aims: This study investigates the relationship between national birth rate and female dementia incidence globally, considering demographic and socioeconomic confounders.Materials & methods: Data from 204 countries were analyzed using bivariate correlation, partial correlation, principal component analysis, and multiple linear regression. Female dementia incidence rate (FDIR) was the dependent variable. Birth rate served as the main predictor, with ageing (life expectancy), genetic predisposition (Biological State Index), economic affluence (GDP PPP), and urban living as confounders.Results: Birth rate demonstrated a significant inverse correlation with female dementia incidence (Pearson's r = -0.772, p < 0.001), remaining robust after adjusting for confounders (partial r = -0.548, p < 0.001). Stepwise regression confirmed birth rate as the strongest independent predictor, explaining 61.6% of the variance in FDIR. Genetic predisposition and ageing were also significant, while economic affluence and urban living had minimal effects. The inverse relationship was more pronounced in developing countries and low-income regions.Conclusions: Lower birth rates were strongly associated with higher female dementia incidence globally. Birth rate should be considered a critical demographic factor in dementia risk prediction and public health planning, particularly in ageing and low-resource settings.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2550897"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144950467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quality of life and psychosocial challenges in metastatic breast cancer: the need for tailored interventions in Turkiye. 转移性乳腺癌的生活质量和社会心理挑战：土耳其需要量身定制的干预措施。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-29 DOI: 10.1080/20565623.2025.2511462

Gul Basaran, Nuri Karadurmus, Fatma Bugdayci Basal, Violet Aroyo, Esra Savas, Ozge Fulya Ozturk Saglam, Pınar Gunay Aslan, Mahmut Gumus

{"title":"Quality of life and psychosocial challenges in metastatic breast cancer: the need for tailored interventions in Turkiye.","authors":"Gul Basaran, Nuri Karadurmus, Fatma Bugdayci Basal, Violet Aroyo, Esra Savas, Ozge Fulya Ozturk Saglam, Pınar Gunay Aslan, Mahmut Gumus","doi":"10.1080/20565623.2025.2511462","DOIUrl":"10.1080/20565623.2025.2511462","url":null,"abstract":"Metastatic breast cancer (MBC) patients face numerous psychosocial difficulties, including physical symptoms, psychological distress, and fears of mortality, which heavily impact their quality of life (QoL). This study addresses the need for culturally and regionally tailored psychosocial interventions by integrating insights from semi-structured interviews with selected stakeholders in Turkiye. Utilizing a qualitative research design, interviews were conducted with a patient association representative, psycho-oncologist, and oncologists with psychological expertise. These interviews, guided by literature-driven questions, lasted about three hours each and explored the challenges MBC patients face, the existing support structures, and the dynamics of patient-doctor interactions in Turkiye. Findings reveal that MBC patients experience significant psychological distress and QoL decline due to economic issues, fears of job loss, societal stigma, family dynamics, and limited psychological support. Effective doctor-patient communication, targeted psychological interventions, and comprehensive family support are essential. Experts advocate for a holistic, psycho-oncological approach, addressing both physical and psychological needs, with recommendations for multidisciplinary care, ongoing psychiatric support, and increased awareness. This study highlights the importance of tailored, patient-centered interventions to improve the QoL of MBC patients in Turkiye.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2511462"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cocaine-associated non-occlusive ischemic colitis mimicking appendicitis in a young woman: a case report. 年轻女性可卡因相关性非闭塞性缺血性结肠炎模拟阑尾炎1例报告。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-10-10 DOI: 10.1080/20565623.2025.2570011

Haythem Elaskri, Sadri Ben Abid, Alaa Oueslati, Sondes Bizid, Sonia Ben Ali, Omar Beskri, Arine Aouadi, Issam Msakni, Hatem Ben Abdallah, Iheb Labbene

引用次数: 0

Computer vision syndrome: a comprehensive literature review. 计算机视觉综合征：综合文献综述。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-08 DOI: 10.1080/20565623.2025.2476923

Fares Kahal, Ahmad Al Darra, André Torbey

{"title":"Computer vision syndrome: a comprehensive literature review.","authors":"Fares Kahal, Ahmad Al Darra, André Torbey","doi":"10.1080/20565623.2025.2476923","DOIUrl":"10.1080/20565623.2025.2476923","url":null,"abstract":"Computer Vision Syndrome is a growing health concern in the digital age, with a reported prevalence of 69.0%. It is caused by screen-related, environmental, ergonomic, and physiological factors, affecting diverse demographics. The COVID-19 pandemic significantly amplified CVS due to increased screen time for remote work, online learning, and social media use, with studies reporting symptoms in up to 74% of individuals. Unique visual challenges from digital screens, including reduced clarity and glare, exacerbate symptoms like dry eyes and discomfort, especially in those with uncorrected vision. Understanding CVS is crucial for mitigating its impact through effective prevention and management strategies. This study explores the causes, diagnosis, management, and prevention strategies of CVS by synthesizing recent findings from optometry, occupational health, digital health, and ergonomics. It also highlights emerging trends such as AI, wearables, and augmented reality while providing practical management strategies. A narrative review of literature from 2014 to 2024 was conducted, focusing on PubMed-indexed, peer-reviewed articles, including meta-analyses and systematic reviews, with priority given to recent, highly cited studies.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2476923"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management. 基于聚合物纳米颗粒的靶向递送药物和生物活性化合物用于关节炎管理。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-20 DOI: 10.1080/20565623.2025.2467591

Tanu Dixit, Anuradha Vaidya, Selvan Ravindran

{"title":"Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management.","authors":"Tanu Dixit, Anuradha Vaidya, Selvan Ravindran","doi":"10.1080/20565623.2025.2467591","DOIUrl":"10.1080/20565623.2025.2467591","url":null,"abstract":"This review explores the potential of polymeric nanoparticles (PNPs) as targeted drug delivery systems for arthritic treatment, overcoming the limitations of the present therapy. A thorough literature search was conducted on the databases PubMed, Scopus, and Web of Science to find published articles on the use of polymeric nanoparticles in the treatment of arthritis. This includes synthesis methods, mechanisms in drug delivery, and applications of PNPs. Polymeric nanoparticles showed excellent promise in the management of arthritis through enhanced stability of drugs, controlled and sustained drug release, and reduced systemic side effects. Some of the highlighted biocompatible and targeting capabilities of natural and synthetic polymers include chitosan, hyaluronic acid, and PLGA. Bioactive compounds such as curcumin and resveratrol delivered by PNPs enhanced therapeutic efficacy in preclinical arthritis models. Despite their promise, challenges such as rapid clearance and manufacturing scalability remain critical barriers. Polymeric nanoparticles offer a transformative approach to arthritis management by enabling targeted, sustained, and safe drug delivery. Translation into clinical applications would thus require developments in nanoparticle design, personalized medicine, and scalable production techniques.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2467591"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell therapies: patient access and affordability solutions. CAR-T细胞疗法：患者可及性和可负担性解决方案。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-29 DOI: 10.1080/20565623.2025.2483613

Elisabete Gonçalves

{"title":"CAR-T cell therapies: patient access and affordability solutions.","authors":"Elisabete Gonçalves","doi":"10.1080/20565623.2025.2483613","DOIUrl":"10.1080/20565623.2025.2483613","url":null,"abstract":"Chimeric Antigen Receptor (CAR)-T cell therapies, as potentially curative treatments, are a group of immunotherapy agents that are changing the paradigm for the treatment of hematologic malignancies. Ongoing research on CAR-T cell therapy is expected to expand the currently approved indications, which, given the high prices of these innovative therapeutic solutions, will increase the pressure on the sustainability of health systems, enhancing the need to establish adjusted financial solutions and promote the implementation of post-marketing monitoring procedures. This study examines the specific challenges in the development of robust clinical evidence to support the value measurement and cost-effectiveness assessment of CAR-T cell therapies and in the selection of adequate financing solutions. Managed Entry Agreements, which create mechanisms in which the risk associated with the uncertainty in long-term outcomes of these therapies is shared between the manufacturer and the payer, have emerged as preferred solutions in several European Union countries. The access barriers to CAR-T cell therapies are described, and recommendations on potential solutions to address affordability concerns using a framework of a life cycle approach to value assessment involving different stakeholders and adapted financing tools are proposed.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2483613"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing tomato-derived small extracellular vesicles as drug delivery system for cancer therapy. 利用番茄衍生的细胞外小泡作为癌症治疗的药物传递系统。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI: 10.1080/20565623.2025.2461956

Kartik Kumar Sarwareddy, Anula Divyash Singh, Sreekanth Patnam, Babiola Annes Sesuraj, Spd Ponamgi, Basant Kumar Thakur, Venkata Sasidhar Manda

{"title":"Harnessing tomato-derived small extracellular vesicles as drug delivery system for cancer therapy.","authors":"Kartik Kumar Sarwareddy, Anula Divyash Singh, Sreekanth Patnam, Babiola Annes Sesuraj, Spd Ponamgi, Basant Kumar Thakur, Venkata Sasidhar Manda","doi":"10.1080/20565623.2025.2461956","DOIUrl":"10.1080/20565623.2025.2461956","url":null,"abstract":"Aim: This study aims to explore a sustainable and scalable approach using tomato fruit-derived sEVs (TsEVs) to deliver calcitriol for enhanced anticancer effects, addressing challenges of low yield and high costs associated with mammalian cell-derived sEVs.Methods: TsEVs were isolated by centrifugation and ultrafiltration and characterized using DLS, TEM, and biochemical assays. Calcitriol was loaded into TsEVs via loading methods, with efficiency measured by spectrophotometry and HPLC. HCT116 and HT29 colon cancer cells were treated with TsEV-calcitriol and assessed for viability, colony formation, migration, ROS levels, and apoptosis gene expression.Results: Isolated TsEVs ranged from 30-200 nm with a protein-to-lipid ratio of ∼1. Calcitriol encapsulation efficiencies were 15.4% (passive), 34.8% (freeze-thaw), and 47.3% (sonication). TsEV-calcitriol reduced HCT116 cell viability with IC50 values of 4.05 µg/ml (24 h) and 2.07 µg/ml (48 h). Clonogenic assays showed reduced colony formation and migration. Elevated ROS levels and increased Bax/Bcl-2 ratio were observed in treated HCT116 and HT29 colon cancer cells.Conclusion: These findings highlight TsEVs as a promising alternative drug delivery platform to mammalian cell-derived sEV for enhancing the therapeutic efficiency of calcitriol and other anticancer agents.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2461956"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Depression among outpatients with diabetic peripheral neuropathy: prevalence and associated factors. 糖尿病周围神经病变门诊患者抑郁：患病率及相关因素

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-31 DOI: 10.1080/20565623.2025.2458989

Besher Gharaibeh, Aya Baniyones, Sawsan Abuhammad, Amat Al-Khaleq O Mehrass

{"title":"Depression among outpatients with diabetic peripheral neuropathy: prevalence and associated factors.","authors":"Besher Gharaibeh, Aya Baniyones, Sawsan Abuhammad, Amat Al-Khaleq O Mehrass","doi":"10.1080/20565623.2025.2458989","DOIUrl":"10.1080/20565623.2025.2458989","url":null,"abstract":"Aim: This study aims to assess the prevalence of depression among patients with diabetic neuropathy and identify contributing factors.Methods: A cross-sectional descriptive design was used, recruiting 153 patients from outpatient clinics. Participants completed the Beck Depression Inventory II, Michigan Neuropathy Screening Instrument, and Douleur Neuropathique 4 questionnaires, with recent A1C results obtained from medical records.Results: The mean depression score was 16.5, with 98 patients (65%) reporting depression and 20 (13%) indicating moderate to severe depression. Approximately half of the sample experienced neuropathy and neuropathic pain. The mean Michigan Neuropathy Screening Instrument score was 5 (SD = 5), and the Douleur Neuropathique 4 score was 4 (SD = 3.5). Regression analyses showed significant demographic influences on depression. Higher Michigan Neuropathy Screening scores predicted greater depression severity, while DN4 scores did not significantly impact depression levels.Conclusions: Depression in patients with diabetic neuropathy is influenced by the severity of neuropathy. Factors commonly associated with depression in diabetes, such as pain intensity and glycemic control, do not significantly affect depression in the context of neuropathy. These findings highlight the complexity of addressing depression in diabetes care, requiring comprehensive and ongoing approaches.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458989"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute pancreatitis revealing duodenal papilla MALT lymphoma: a case report and review of the literature. 急性胰腺炎显露十二指肠乳头MALT淋巴瘤：1例报告及文献复习。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-05-06 DOI: 10.1080/20565623.2025.2497206

Wafa Dahmani, Houssem Hassan, Aya Hammami, Aida Ben Slama, Ahlem Brahem, Hanene Jaizri, Nour Elleuch, Mehdi Ksiaa

{"title":"Acute pancreatitis revealing duodenal papilla MALT lymphoma: a case report and review of the literature.","authors":"Wafa Dahmani, Houssem Hassan, Aya Hammami, Aida Ben Slama, Ahlem Brahem, Hanene Jaizri, Nour Elleuch, Mehdi Ksiaa","doi":"10.1080/20565623.2025.2497206","DOIUrl":"https://doi.org/10.1080/20565623.2025.2497206","url":null,"abstract":"Mucosa-associated lymphoid tissue (MALT) lymphoma is a rare subtype of non-Hodgkin lymphoma, predominantly found in the gastrointestinal tract, particularly the stomach. However, its localization at the ampulla of Vater is exceptionally rare and presents considerable diagnostic challenges. This atypical presentation can easily mimic more common conditions, such as ampullary tumors or pancreaticobiliary disorders, making accurate diagnosis and management particularly complex. We present the case of a 70-year-old woman who initially presented with obstructive jaundice and acute pancreatitis, ultimately revealing a diagnosis of MALT lymphoma at the duodenal papilla. She was managed with combination of Helicobacter pylori eradication therapy followed by chemotherapy. This case emphasizes the importance of considering lymphoproliferative disorders in the differential diagnosis of biliary obstruction and pancreatitis, highlighting the need for heightened awareness among clinicians. Through this unique case, we aim to contribute to the limited literature on MALT lymphoma at the ampulla of Vater, illustrating both the complexities of diagnosis and the potential for successful management strategies in rare gastrointestinal lymphomas.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2497206"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer. 经动脉化疗栓塞联合杜伐单抗治疗晚期和转移性胆道癌的临床疗效

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-04 DOI: 10.1080/20565623.2025.2526947

Yuefeng Hu, Jian Wei, Xuedong Sun, Guang Chen, Tianhao Su, Zeran Yang, Xu Lu, Long Jin

{"title":"Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer.","authors":"Yuefeng Hu, Jian Wei, Xuedong Sun, Guang Chen, Tianhao Su, Zeran Yang, Xu Lu, Long Jin","doi":"10.1080/20565623.2025.2526947","DOIUrl":"10.1080/20565623.2025.2526947","url":null,"abstract":"Background: This study aimed to evaluate the safety and efficacy of TACE combined with durvalumab for treating advanced and metastatic BTC. Research design and methods: Data were collected retrospectively from a single center. The TACE procedures were performed 1 to 19 times, with repetitions occurring every 4 to 12 weeks based on the patient's liver function and tumor shrinkage. Durvalumab was given as an intravenous injection every three weeks at a dose of 1000 to 1500 mg.Results: The estimated median progression-free survival (PFS) was 9.0 months (95% CI: 6.8 to 11.2), with a 1-year PFS rate of 23.8%. The estimated median overall survival (OS) was 16.0 months (95% CI: 7.5 to 24.5), with a 1-year OS rate of 58.7%. The investigator-confirmed objective response rate (ORR) was 35.9%. Elevated baseline carcinoembryonic antigen (CEA) levels and neutrophil-to-lymphocyte ratio (NLR) ≥ 3 showed negative correlations with PFS (p = 0.035, CEA; p = 0.038, NLR) and OS (p = 0.040, NLR). Adverse events occurred in 36 patients (92.3%). Additionally, 7 patients (17.9%) experienced immune-mediated AEs (imAEs).Conclusions: These results indicate promising efficacy and acceptable safety for the combination of TACE and durvalumab as a first-line treatment for advanced and metastatic BTC.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2526947"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0